Baird Financial Group
NRIX icon

Baird Financial Group’s Nurix Therapeutics NRIX Stock Holding History

Baird Financial Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-110,000
Closed -$1.25M – 1832
2025
Q2 		$1.25M Buy
+110,000
New +$1.19M ﹤0.01% 1154

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baird Financial Group's NRIX Position: Q3 2025 in Review

Baird Financial Group sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 110,000 shares — an estimated $1.25M sold.

Baird Financial Group first reported a position in NRIX in Q2 2025 and held it in 1 quarter. The position peaked at $1.25M in Q2 2025. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

  • Baird Financial Group reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Baird Financial Group sold 110,000 Nurix Therapeutics shares in Q3 2025, an estimated $1.25M.
  • Baird Financial Group first reported a position in Nurix Therapeutics in Q2 2025 and held it in 1 quarter.
  • Baird Financial Group's Nurix Therapeutics position peaked at $1.25M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Baird Financial Group's 13F filing for Q3 2025, filed 13 Nov 2025.